Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Easy 100% gain from here by next Friday!
Those who wanted to sell are out! UP we go, look for a big run into the close
$VDRM
MMs want you shares! Don't fall for the games!
They know we will run hard next week!! Buying will come back!
$VDRM
~ CEO speaking at the Global Diabetic Foot Conference in Houston March 23-25, 2017 ~
http://www.marketwired.com/press-release/dr-chris-ayo-otiko-president-viaderma-inc-is-selected-write-article-healing-diabetic-otc-pink-vdrm-2194656.htm
http://dfcon.com
https://www.drugs.com/otc/676986/viabecline.html
https://www.linkedin.com/pulse/healing-diabetic-ulcers-dave-pozek-1
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=129403043
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=129390203
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=129368069
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=129334996
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=129312100
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=129311752
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=129297007
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=129296364
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=129295215
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=129286262
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=129196331
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=129040891
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=128962099
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=128961948
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=128957163
Starosolska, Joanna <Joanna.Starosolska@bcm.edu>
9:39 AM Wednesday, March 15, 2017
to me
Good morning,
Dr. Otiko has been invited to present his poster during the poster session at DFCon. This is a formal session, but it is not an exclusive speaking event.
Poster session will take place on March 24 from 11:40 am to 2:20 pm.
With kind regards,
Joanna Starosolska
Administrative Secretary
Division of Vascular Surgery
Baylor College of Medicine
One Baylor Plaza, MS 390
Houston, TX 77030
Ph: 713-798-7851
Fx: 713-798-2744
DFCon 2017
cid:image004.jpg@01D12770.3F6AF690
I think we will make a run into the close today! Next week will be BIG
http://stockcharts.com/h-sc/ui?s=vdrm
https://www.tradingview.com/x/bKKkny0f/
I feel we are on a breakout, here's why..
Thursday, January 12, .006, Friday close.008 ~ the following week we ran to .017
Thursday, February 2, .009, Friday close.014 ~ the following week we ran to .03
Thursday, February 16, .018, Friday close.019 ~ the following week we ran to .069
Thursday, March 16, .0274,
The charts look perfect for the next leg up, and with the conference looming next week, I feel we will see a breakout.
Long $VDRM
goldenisla Monday, 02/27/17 06:28:35 PM
Re: tomadam post# 12413
Post # of 15426
Thank you for sharing that info. Was there anything else mentioned?... also it seems strange that he would have time to talk to individual investors?
By the way I started a position here today at .041 I may buy more if these forecasted dips actually happen.
Charts don't lie. Learn how to read them
When we hit .25 and pull back to .175, the chart will look good for a reversal there as well.
Next week is going to BIG
Long $VDRM
People look at these charts very carefully..
http://stockcharts.com/h-sc/ui?s=vdrm
https://www.tradingview.com/x/bKKkny0f/
I feel we are on a breakout, here's why..
Thursday, January 12, .006, Friday close.008 ~ the following week we ran to .017
Thursday, February 2, .009, Friday close.014 ~ the following week we ran to .03
Thursday, February 16, .018, Friday close.019 ~ the following week we ran to .069
Thursday, March 16, .0274,
The charts look perfect for the next leg up, and with the conference looming next week, I feel we will see a breakout.
Long $VDRM
I'm in at .0002. Looks like a good play!
Let see what happens
Bought some at .0002, thanks for the tip.
Lets see what happens
Starosolska, Joanna <Joanna.Starosolska@bcm.edu>
9:39 AM Wednesday, March 15, 2017
to me
Good morning,
Dr. Otiko has been invited to present his poster during the poster session at DFCon. This is a formal session, but it is not an exclusive speaking event.
Poster session will take place on March 24 from 11:40 am to 2:20 pm.
With kind regards,
Joanna Starosolska
Administrative Secretary
Division of Vascular Surgery
Baylor College of Medicine
One Baylor Plaza, MS 390
Houston, TX 77030
Ph: 713-798-7851
Fx: 713-798-2744
DFCon 2017
cid:image004.jpg@01D12770.3F6AF690
February 8, 2017
~ CEO speaking at the Global Diabetic Foot Conference in Houston March 23-25, 2017 ~
http://www.marketwired.com/press-release/dr-chris-ayo-otiko-president-viaderma-inc-is-selected-write-article-healing-diabetic-otc-pink-vdrm-2194656.htm
http://dfcon.com
https://www.drugs.com/otc/676986/viabecline.html
https://www.linkedin.com/pulse/healing-diabetic-ulcers-dave-pozek-1
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=129403043
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=129390203
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=129368069
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=129334996
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=129312100
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=129311752
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=129297007
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=129296364
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=129295215
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=129286262
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=129196331
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=129040891
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=128962099
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=128961948
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=128957163
Reversal has started today, next week we will run BIG! The one short left will be no longer soon!!
$VDRM
VDRM ~ ViaDerma ~ currently trading at .028 I'm pretty BIG on this company.
Maybe not the time to read all the DD below but here it is for those who want to get on on a COMPLETELY oversold amazing little company with a Market Cap of only $5.6mill
The CEO is speaking at http://dfcon.com next March 23-25
Biotech play
Medical MJ play
March 8, 2017
~ Sales, labeling & marketing being launched!! Industry expert hired!! ~
http://www.marketwired.com/press-release/viaderma-inc-hires-product-rollout-expert-manage-quality-control-labeling-marketing-pinksheets-vdrm-2201662.htm
~Ivan Klarich Reviews~
https://www.linkedin.com/in/ivanklarich/
Aidan Roark Makepeace
Founder/CEO at WRKPRTY
Aidan Roark worked with Ivan in different groups
I have had the privilege of working with and for Ivan on several software development and business strategy projects ranging from the start-up to the enterprise level and can say, without reservation, Ivan is amazing to work with. Ivan is a thoughtful and inspiring leader and team-builder, and an energetic, diligent, and reliable visionary in strategic planning and operations/executive management. I welcome every opportunity to work with Ivan and can wholeheartedly recommend his services, as well as those of his extensive team of associates.
Mireille Buiel
HR Lead at FindHotel
Mireille worked with Ivan but at different companies
I have worked together with Ivan as consultants at a California based FMCG manufacturing company. I got to know him as a value-based strategic thinker that keeps his eye on the long-term goal. He is able to bring teams and entrepreneurs quickly to the ‘pain points’ and find new practical solutions for their business (model) issues. I would definitely recommend him for complex organizational and commercial challenges.
John Fanaris
Co-Owner/GM/Sommelier at Rustic Kitchen
John worked with Ivan but at different companies
Preparing for growth and putting the right pieces together are crucial to success and Ivan brings the tools needed to the table. He has a non-confrontational demeanor in his analysis of your internal methodology with the uncanny knack of straight forward communication and a tell-it-like-it-is constructive advice. He is an expert at analyzing company operations and culture to develop a comprehensive strategy to reach your goals. If you are looking to take your company to the next level, Ivan is your man.
Jackie Lapin / Authors, Speakers, Get Leads, Get Booked
?? AUTHORS & SPEAKERS, GET LEADS, GET BOOKED–Book Your Own Speaking Engagements at Transformational Venues & Events
Jackie Lapin / worked with Ivan but at different companies
Ivan is one of the most brilliant forward-thinking business visionaries I've ever encountered. That skill is anchored by real world practical strategic analytics and implementation that ensures success. I want him on my team whenever I'm launching something new, improve what's already working or need to fix something that's not!
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=129418493
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=129409088
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=129402020
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=129401494
http://www.hopedance.org/home/awakenings/2920-virtual-realty-enters-the-arena-to-help-people-overcome-their-co-dependency-on-outside-approval-to-achieve-an-emotionally-free-high-performance-happy-life
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=129344707
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=129339497
February 15, 2017
~ Additional patents are being filed in the MMJ space! ~
http://www.marketwired.com/press-release/viaderma-inc-looks-file-additional-patents-license-new-products-its-mmj-medical-marijuana-otc-pink-vdrm-2196107.htm
http://www.thedailychronic.net/2017/68842/clinical-trial-thcv-lowers-blood-sugar-levels-in-type-2-diabetics/
http://www.thedailychronic.net/2017/69698/study-medical-cannabis-patients-reduce-their-use-of-opioids/
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=129340717
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=129277006
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=129022846
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=129017714
February 8, 2017
~ CEO speaking at the Global Diabetic Foot Conference in Houston March 23-25, 2017 ~
http://www.marketwired.com/press-release/dr-chris-ayo-otiko-president-viaderma-inc-is-selected-write-article-healing-diabetic-otc-pink-vdrm-2194656.htm
http://dfcon.com
https://www.drugs.com/otc/676986/viabecline.html
https://www.linkedin.com/pulse/healing-diabetic-ulcers-dave-pozek-1
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=129403043
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=129390203
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=129368069
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=129334996
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=129312100
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=129311752
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=129297007
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=129296364
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=129295215
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=129286262
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=129196331
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=129040891
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=128962099
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=128961948
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=128957163
February 3, 2017
~ MASSIVE sales coming.. 500,000 units x $125 = $62,500,000 in 2017~
http://www.marketwired.com/press-release/viaderma-inc-targets-online-sales-wound-care-centers-distribution-companies-its-viabecline-pinksheets-vdrm-2193323.htm
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=129402236
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=129339194
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=129286070
January 11, 2017
~Filed a patent application with the USPTO for its proprietary innovative transdermal delivery system~
http://www.marketwired.com/press-release/viaderma-incs-ceo-files-new-patent-application-signs-two-licensing-deals-locates-product-otc-pink-vdrm-2187878.htm
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=129386093
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=129283860
November 30, 2016
"Patent Pending Transdermal System" can deliver medications and nutrients into the body through the skin. The solution combined with FDA registered drugs can increase the absorption as much as 100 times directly to the localized treatment areas,
http://www.marketwired.com/press-release/viaderma-inc-clinical-studies-abroad-europe-middle-east-asia-show-promising-results-otc-pink-vdrm-2179850.htm
November 14, 2016
Filed Patent Pending use of its innovative transdermal system for the delivery of (CBD's) Calanoids and (THC) Tetrahydrocannabinol for the treatment of several diseases
http://www.marketwired.com/press-release/viaderma-inc-enters-mmj-medical-marijuana-industry-with-patent-pending-cbd-delivery-otc-pink-vdrm-2175498.htm
Current Market Cap ~ $5.6mill, March 16, 2017~
Share Structure
Authorized Shares 400,000,000 a/o Mar 07, 2017
Outstanding Shares 321,232,603 a/o Mar 07, 2017
-Restricted 57,975,478 a/o Mar 07, 2017
-Unrestricted 263,257,125 a/o Mar 07, 2017
Held at DTC 246,331,609 a/o Mar 07, 2017
Float 222,337,825 a/o Jan 25, 2017
2dollarbill ~ REPOST
just doing my part here...
Lead Product TetraStem
World’s strongest broad spectrum tetracycline-based topical antibiotic with proven results. Used for cuts, scrapes, wounds, infections, burns, acne, psoriasis, eczema, and minor injuries.
Very low water content and optimum (low) viscosity. Uses both a chemical AND physical kill mechanism which is advantageous over traditional antibiotics which use only a chemical kill mechanism and has a better resistance profile.
Potential Markets
ViaDerma is developing products in many fields of use, including:
Topical antibiotics- $6 billion/year
Toenail antifungal drugs- $3 billion/year
Diabetic amputations- $3 billion/year
Global acne- $3.02 billion/year
Psoriasis- $7.3 billion/year
Eczema- $2.5 billion/year
Other potential markets include burns, anti-aging/wrinkle remover cream, medical cannabis, male-pattern baldness, skin cancer, erectile dysfunction, and pain management. Innovative, patent pending dual carrier transdermal technology which can transform oral medication into topical products. Ability to enable active ingredients with a rapid transport direct to the site of action.
Ability to be used in any field including Sports Nutrition Supplements, Cosmetics, First Aid Products, Wound Care, and Skin Diseases like Acne, Eczema, and Psoriasis. Dual carrier liquid which can possess life enhancing technology with up to four year shelf-life. Facilitates transfer of chemicals through the stratum corneum with a diffusion constant 10,000x higher. Strong Advanced Biological Coverage (ABC) which has higher concentrations, faster penetration and is more effective than conventional antibiotics. ABC produces desirable results in ~24 hours or less compared to 5-7 days. It kills all harmful gram-positive and gram-negative bacteria that have been available for testing.
1- back in 2.25.2014 philips manufactured there last fda approval of tetrastem, its a 3 year shelf life as im able to see
2 - in 5.28.2014 VDRM started to manufacture there first fda approval of tetrastem, same 3 year shelf life
3 - now heres where it make huge sense in 3.2014 VDRM gets the rights to manufacture tetrastem from phlips....1 month after they start there first manufacture of tetrastem
4 - the 3 - 6 - 9 month studies kick in in a huge way, and now VDRM as of 1.2017 manufactures 500,000 bottles for sale,
...basically they took what worked expanded on it and said this is huger than we thought
5 - 12.2016 VDRM files for uopdated Viabecline patent - which is purely application - so that means anyone, anywhere, anytime they use tetrastem - pure play on licensing application
6 - back in 2015 rumors started that both PFE and MRK and Endo pharma were looking at VDRM
7 - 2.2017 Dr Otiko to write a paper on diabetic ulcers showing massive results - which means all roads to viabecline
articles of interest ( get them off the web )
1 - from a 2.2011 study reposted in 1.2017 paraplegic uses tetrastem with stem cells and walks again ( philips put the article out )
2 - 3.2015 onychmycosis article
3 - 11.2016 viabecline article
4 - 12.2016 diabetic ulcers study vdrm issued
5 - 12.2016 viabecline patent applied for
6 - 1.2017 vdrm 500,000 bottles manufactured for 2017 grossing 62-65M in sales
viabecline is a delivery of tetrastem - which can take any oral as well and apply to ointment application
PFE is all about viagra, now imagine a lotion for f on f , not just a pill, and youve opened a huge market in the world away of same sex...mrk is all about diabetes and with application wise they want in too, add in JNJ which bandaids work and graduate to a 1000% increase in healing and they want in too...
VDRM product is 85% cheaper and works better - Viabecline is what the entire game is all about here - application technology
PFE Viagra is a category killer but it is a pill - and a pill is a introduction internally to the blood stream which out of fear a great portion of the population will just not take, now factor in a female Viagra alternative that is topical and replace the male Viagra with the same topical and its obvious that PFE will be forced to enter some sort of licensing agreement to hold onto there market share and as well look to capitalize on the female market as well ( m on f , and f on f ) there are those that will only use topical not internal
MRK, LLY and MNKD are the diabetic market and its huge - toenail fungal market - now add on a turnaround solution they have been needing for years, to treat at home foot infections ( home care largest market globally ) and that market alone is extraordinary with multiple companies all vying to be the dominant player and VDRM having the solution to license
JNJ marketplace is wounds - the band , now graduate it to the ability to speed the process up say 10 fold to heal any scrapes scratched wounds and to hold there market-share JNJ will be forced to enter some sort of licensing deal just to hold the line or risk crippling there empire quite easily
MRK and JNJ baldness market is in a level all itself, as its a do it yourself world we live in - add a just for men/ ladies crowd solution to expand into the baldness market and make that a CVS Walgreen's etc play for direct access more licensing
without even touching on the other markets there is exceptional growth here
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
~Info on Dr. Chris Otiko, CEO of ViaDerma~
Radio interview from December 9, 2016. https://upticknewswire.com/viaderma-ceo-dr-chris-otiko-talks-active-treatments-for-diabetic-wounds/
https://www.linkedin.com/in/chris-ayo-otiko-80284b5/
https://www.linkedin.com/pulse/healing-diabetic-ulcers-viabecline-new-topical-antibiotic-otiko
https://www.barbadostoday.bb/2014/07/05/miracle-drug-for-diabetics/
http://www.neurogenx.com/testimonial/christopher-otiko-dpm-ceo-executive-medical-director/
https://www.ratemds.com/doctor-ratings/2334438/Dr-Christopher+A.-Otiko-Reseda-CA.html
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=129394138
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=129356678
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=129353170
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=129346970
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=129340283
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=129311397
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=129294386
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=129283754
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=129265204
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=129223612
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=129222563
~Patent/Licensing/Manufacturing Info~
https://www.drugs.com/otc/129916/tetrastem.html
(licensed as Diabecline and Viabecline). Regardless of who owns or has the rights to the patent, ViaDerma has licensing rights, and has filed a new patent pending application for the transdermal system as per January 11, 2017 PR
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=129289616
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=129282983
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=129282283
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=129280927
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=129279832
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=129273942
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=129273861
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=129234169
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=129232328
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=129224588
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=129224450
investorshub.advfn.com/boards/read_msg.aspx?message_id=129224065
Interesting posts!
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=129413941
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=129397880
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=129394039
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=129392467
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=129386665
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=129383996
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=129357204
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=129351881
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=129346142
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=129334810
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=129329694
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=129308249
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=129278022
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=129268497
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=129200839
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=129127030
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=129126891
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=129022830
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=129011372
GLTA
LONG $VDRM
Your pics are awesome!!
$VDRM
A run to .05 heading into the conference is NOT excessive IMHO
We are also SIGNIFICANTLY oversold!
http://stockcharts.com/h-sc/ui?s=vdrm
I think we will hit new highs post conference. (.069)
With any good PRs, I am still hopeful of my targets for March of .10-12+
$VDRM
VDRM breakout! Reversal has started! Conference is her next week!! A run to over .05 heading into the conference is as close to a certainty as you can get! IMHO
Oversold! http://stockcharts.com/h-sc/ui?s=vdrm
Read EVERYTHING below!!
February 8, 2017
~ CEO speaking at the Global Diabetic Foot Conference in Houston March 23-25, 2017 ~
http://www.marketwired.com/press-release/dr-chris-ayo-otiko-president-viaderma-inc-is-selected-write-article-healing-diabetic-otc-pink-vdrm-2194656.htm
https://www.drugs.com/otc/676986/viabecline.html
https://www.linkedin.com/pulse/healing-diabetic-ulcers-dave-pozek-1
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=129403043
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=129390203
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=129368069
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=129334996
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=129312100
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=129311752
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=129297007
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=129296364
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=129295215
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=129286262
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=129196331
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=129040891
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=128962099
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=128961948
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=128957163
My pleasure!! ViaDerma will make LONGS very very wealthy!!!
Conference should bring in some new momentum, I think it should run this week and next and hit news highs, if not next week, the week following the conference. Any PR update about the conference would be huge.
I'm hopeful that Chris and this new IR guy are updating their website with all relevant patent info. I expect a PR with this announcement. The CEO has verified that the have '2' patent pending application numbers, one for the transdermal technology for Viabecline and the other for their technology and THC and CBD (Cannabinoids).
Another PR will come announcing some type of MMJ licensing agreement. This potentially will send us north of .50 with this announcement.
Another PR could be announced on sales.
I'm hopeful of 4 PRs coming, if they all land this month or next, we're talking $$'s
We need to build the moment back up. It wouldn't take much to move back up over .05 with the conference alone..
I've done extensive DD
$VDRM
I think we are going to pop BIG today people! We are coiled!
Spread the word of the conference next week, and .05+ will be here next week!
February 8, 2017
~ CEO speaking at the Global Diabetic Foot Conference in Houston March 21-23, 2017 ~
http://www.marketwired.com/press-release/dr-chris-ayo-otiko-president-viaderma-inc-is-selected-write-article-healing-diabetic-otc-pink-vdrm-2194656.htm
http://dfcon.com
https://www.drugs.com/otc/676986/viabecline.html
https://www.linkedin.com/pulse/healing-diabetic-ulcers-dave-pozek-1
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=129403043
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=129390203
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=129368069
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=129334996
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=129312100
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=129311752
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=129297007
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=129296364
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=129295215
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=129286262
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=129196331
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=129040891
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=128962099
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=128961948
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=128957163
Reversal has started! Conference is her next week!! A run to over .05 heading into the conference is as close to a certainty as you can get! IMHO
Read EVERYTHING below!!
February 8, 2017
~ CEO speaking at the Global Diabetic Foot Conference in Houston March 23-25, 2017 ~
http://www.marketwired.com/press-release/dr-chris-ayo-otiko-president-viaderma-inc-is-selected-write-article-healing-diabetic-otc-pink-vdrm-2194656.htm
https://www.drugs.com/otc/676986/viabecline.html
https://www.linkedin.com/pulse/healing-diabetic-ulcers-dave-pozek-1
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=129403043
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=129390203
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=129368069
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=129334996
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=129312100
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=129311752
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=129297007
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=129296364
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=129295215
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=129286262
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=129196331
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=129040891
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=128962099
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=128961948
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=128957163
stockzoom Wednesday, 03/08/17 09:13:12 AM
Re: None
Post # of 15339
Got another email in the evening from Doc, we should have PR soon. They are also going to create IR team now for more updates on CBD trials they will start. That is great news. This is now becoming more and more like OWCP as larger CBD trials start. Great buy and hold medical MJ play + Biotech on Diabetic foot ulcer makes it TWIN investment
Medical MJ + Biotech
The good news is Medical MJ will not be affected by current administration policies Sessions has made it clear. Money is moving out of recreational MJ stocks to medical MJ stocks
Looking forward to big news ahead very soon, we will get some CBD updates too, that' what I am interested to hear
The float here is tiny unlike other MJ stocks, that helps a lot
Minimum 20-25 cents stock if we match OWC@P, CB@IS and CNB@X current market cap valuation. This is deeply undervalued with massive upside in next few months as PR start flowing and we get more CBD trial updates as Doc told
I am more excited after doc's email's to hear about CBD trials now..I know patent means a lot. I want to know more about CBD trials progress they have made
That's going to drive the stock lot higher !
I'm surprised we haven't seen an upward movement in share price yet. I suppose volume is too low.
It'll come. Let's spread the word of the conference next week, March 22-24th.
I believe we will see increased volume heading into the conference and a big push up...
Going to be a good run coming!
$VDRM
GreenBrickRoad, you're a new a MOD here..
Great things coming!
$VDRM
Great post! We have a GOLD mine here, and it hasn't even started to get mined yet.. Look back here in a years time.. the day to day chatter won't matter for long.
My recommendation is to BUY a stake here, whatever you're comfortable holding, and let it ride.
REPOST
January 11, 2017
~Filed a patent application with the USPTO for its proprietary innovative transdermal delivery system~
http://www.marketwired.com/press-release/viaderma-incs-ceo-files-new-patent-application-signs-two-licensing-deals-locates-product-otc-pink-vdrm-2187878.htm
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=129386093
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=129283860
November 30, 2016
"Patent Pending Transdermal System" can deliver medications and nutrients into the body through the skin. The solution combined with FDA registered drugs can increase the absorption as much as 100 times directly to the localized treatment areas,
http://www.marketwired.com/press-release/viaderma-inc-clinical-studies-abroad-europe-middle-east-asia-show-promising-results-otc-pink-vdrm-2179850.htm
And Longs don't share your perspective. This is why Chris hired an Industry EXPERT. It's apparent he is hiring help and building out his team.
This is why we are only a $7.9mill Market Cap, and trading at these unbelievably low prices.
Great buying opportunity here people.
Again, read below or call the IR dept
March 8, 2017
~ Sales, labeling & marketing being launched!! Industry expert hired!! ~
http://www.marketwired.com/press-release/viaderma-inc-hires-product-rollout-expert-manage-quality-control-labeling-marketing-pinksheets-vdrm-2201662.htm
~Ivan Klarich Reviews~
https://www.linkedin.com/in/ivanklarich/
Aidan Roark Makepeace
Founder/CEO at WRKPRTY
Aidan Roark worked with Ivan in different groups
I have had the privilege of working with and for Ivan on several software development and business strategy projects ranging from the start-up to the enterprise level and can say, without reservation, Ivan is amazing to work with. Ivan is a thoughtful and inspiring leader and team-builder, and an energetic, diligent, and reliable visionary in strategic planning and operations/executive management. I welcome every opportunity to work with Ivan and can wholeheartedly recommend his services, as well as those of his extensive team of associates.
Mireille Buiel
HR Lead at FindHotel
Mireille worked with Ivan but at different companies
I have worked together with Ivan as consultants at a California based FMCG manufacturing company. I got to know him as a value-based strategic thinker that keeps his eye on the long-term goal. He is able to bring teams and entrepreneurs quickly to the ‘pain points’ and find new practical solutions for their business (model) issues. I would definitely recommend him for complex organizational and commercial challenges.
John Fanaris
Co-Owner/GM/Sommelier at Rustic Kitchen
John worked with Ivan but at different companies
Preparing for growth and putting the right pieces together are crucial to success and Ivan brings the tools needed to the table. He has a non-confrontational demeanor in his analysis of your internal methodology with the uncanny knack of straight forward communication and a tell-it-like-it-is constructive advice. He is an expert at analyzing company operations and culture to develop a comprehensive strategy to reach your goals. If you are looking to take your company to the next level, Ivan is your man.
Jackie Lapin / Authors, Speakers, Get Leads, Get Booked
?? AUTHORS & SPEAKERS, GET LEADS, GET BOOKED–Book Your Own Speaking Engagements at Transformational Venues & Events
Jackie Lapin / worked with Ivan but at different companies
Ivan is one of the most brilliant forward-thinking business visionaries I've ever encountered. That skill is anchored by real world practical strategic analytics and implementation that ensures success. I want him on my team whenever I'm launching something new, improve what's already working or need to fix something that's not!
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=129418493
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=129409088
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=129402020
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=129401494
http://www.hopedance.org/home/awakenings/2920-virtual-realty-enters-the-arena-to-help-people-overcome-their-co-dependency-on-outside-approval-to-achieve-an-emotionally-free-high-performance-happy-life
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=129344707
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=129339497
What do you think?? Read everything below..
February 8, 2017
~ CEO speaking at the Global Diabetic Foot Conference in Houston March 21-23, 2017 ~
http://www.marketwired.com/press-release/dr-chris-ayo-otiko-president-viaderma-inc-is-selected-write-article-healing-diabetic-otc-pink-vdrm-2194656.htm
http://dfcon.com/
https://www.drugs.com/otc/676986/viabecline.html
https://www.linkedin.com/pulse/healing-diabetic-ulcers-dave-pozek-1
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=129403043
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=129390203
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=129368069
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=129334996
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=129312100
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=129311752
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=129297007
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=129296364
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=129295215
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=129286262
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=129196331
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=129040891
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=128962099
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=128961948
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=128957163
ddtburg, good post. Everyone who wanted out, is out. We will move up from here over the next 2 weeks. I believe our run will be significant
$VDRM
People read everything below. The company has confirmed they will be updating their website with patent filings. How many times does this have to be brought up?
The CEO, Dr Chris Otiko, has verified that the have '2' patent pending application numbers, one for the transdermal technology for Viabecline and the other for their technology and THC and CBD (Cannabinoids).
This is why they hired an Investor Relations EXPERT
March 8, 2017
~ Sales, labeling & marketing being launched!! Industry expert hired!! ~
www.marketwired.com/press-release/viaderma-inc-hires-product-rollout-expert-manage-quality-control-labeling-marketing-pinksheets-vdrm-2201662.htm
~Ivan Klarich Reviews~
https://www.linkedin.com/in/ivanklarich/
Aidan Roark Makepeace
Founder/CEO at WRKPRTY
Aidan Roark worked with Ivan in different groups
I have had the privilege of working with and for Ivan on several software development and business strategy projects ranging from the start-up to the enterprise level and can say, without reservation, Ivan is amazing to work with. Ivan is a thoughtful and inspiring leader and team-builder, and an energetic, diligent, and reliable visionary in strategic planning and operations/executive management. I welcome every opportunity to work with Ivan and can wholeheartedly recommend his services, as well as those of his extensive team of associates.
Mireille Buiel
HR Lead at FindHotel
Mireille worked with Ivan but at different companies
I have worked together with Ivan as consultants at a California based FMCG manufacturing company. I got to know him as a value-based strategic thinker that keeps his eye on the long-term goal. He is able to bring teams and entrepreneurs quickly to the ‘pain points’ and find new practical solutions for their business (model) issues. I would definitely recommend him for complex organizational and commercial challenges.
John Fanaris
Co-Owner/GM/Sommelier at Rustic Kitchen
John worked with Ivan but at different companies
Preparing for growth and putting the right pieces together are crucial to success and Ivan brings the tools needed to the table. He has a non-confrontational demeanor in his analysis of your internal methodology with the uncanny knack of straight forward communication and a tell-it-like-it-is constructive advice. He is an expert at analyzing company operations and culture to develop a comprehensive strategy to reach your goals. If you are looking to take your company to the next level, Ivan is your man.
Jackie Lapin / Authors, Speakers, Get Leads, Get Booked
?? AUTHORS & SPEAKERS, GET LEADS, GET BOOKED–Book Your Own Speaking Engagements at Transformational Venues & Events
Jackie Lapin / worked with Ivan but at different companies
Ivan is one of the most brilliant forward-thinking business visionaries I've ever encountered. That skill is anchored by real world practical strategic analytics and implementation that ensures success. I want him on my team whenever I'm launching something new, improve what's already working or need to fix something that's not!
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=129418493
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=129409088
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=129402020
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=129401494
http://www.hopedance.org/home/awakenings/2920-virtual-realty-enters-the-arena-to-help-people-overcome-their-co-dependency-on-outside-approval-to-achieve-an-emotionally-free-high-performance-happy-life
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=129344707
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=129339497
New here. Glad I found SunnySideStockSelections
Rubyt Sunday, 02/12/17 08:46:16 PM
Re: None
Post # of 15150
Vdrm should zoom past .10 after more news in March. Could go to $1 by year end as sales pile up. Big pharma will make a play in 2018 - let's hope we don't sell out for a only a few $ per share. This company has potential to trade way north of $10 as sales pick up in just a year or two at the most. There are many other biotech firms trading much higher with less.
Chart sucks! ...at the moment.. But we are a way OVERSOLD
Chart looks good for a big reversal
http://stockcharts.com/h-sc/ui?s=vdrm
$VDRM
I agree. Watch for a reversal this week. Chart looks good
http://stockcharts.com/h-sc/ui?s=vdrm
$VDRM
I think we will see GREEN days the rest of this week heading into the weekend
$VDRM
My pleasure kennyt 335!
I think we will hit new highs heading into the conference next week as word spreads.
$VDRM
Your welcome! Longs know what we have. I do it for new investors buying in.
I follow many other stocks, however, this is my biggest otc holding, and will have EXPLOSIVE growth this year. I hold many shares here and don't take investing in ViaDerma lightly. I've done extensive DD
Long $VDRM
Oh really!?! .10-12+ post conference price target! You'll see..
dfcon.com/program-guide/
2017 DFCon Houston Diabetic Foot Global Conference
Royal Sonesta Hotel – 222 West Loop South, Houston, TX 77027
March 23-25, 2017
PDF Download Version: Mailed-Program-DFCon-2017
Co-Founder and Co-Chair: David G. Armstrong, DPM, MD, PhD
Co-Chair: Joseph L. Mills, Sr., MD
Co-Founder and Chair Emeritus: George Andros
Course Directors: Bijan Najafi, PhD, MSc and Miguel Montero-Baker, MD
Thursday – March 23, 2017
6:45 – 8:00 Registration
7:00 – 8:00 Breakfast Symposium (non CME/CPME)
Sponsor: Hanger Clinic – Gait Salvage or Limb Salvage: Mobility Matters
– Dr. David Armstrong, Thomas Dibello, CO and Eric Burn, CO – Legends I
GLOBAL SESSION – Strategic Amputation Limitation Summit: Global Treaties to Treat, Trust and Verify Moderators: Dr. David G. Armstrong and Dr. Joseph L. Mills
8:00 – 8:20 Game of Toes: Boulton Unveils the Stark Truths on Amputation Prevention – Dr. Andrew Boulton
8:20 – 8:40 A View of the Diabetic Foot from Down Under – Dr. Matthew Malone
8:40 – 9:00 Toward Forming A More Perfect Union of Native American Nations – How Two Clinicians Serve with a Single Purpose to Save Soles – Dr. Scott Brannan and Dr. Keith Goss
9:00 – 9:20 Toe and Flow Alla Toscana: How Longstanding Leadership Extends Limb Life – Dr. Roberto Anichini
9:20 – 9:40 Pax Romania: How to Create a Diabetic Foot Podiatry Specialty without Stopping for a Bucharest – Dr. Norina Gavan
9:40 – 10:00 Res Ipsa Toequitur: How the National UK Diabetic Foot Audit Is an Indictment and Clemency – Dr. Gerry Rayman and Dr. William Jeffcoate
10:00 – 10:20 The New Look International Working Group on the Diabetic Foot: Moving Forward to Prevent Amputations – Dr. Kristien Van Acker
10:20 – 10:40 Panel Discussion
10:40 – 11:00 Break
Local Recipes for Limb Salvage Team Success
11:00 – 11:10 Avoiding the Chop in Chiapas: Building a Limb Salvage Program in Mexico – Dr. Jose Antonio Muñoa
11:10 – 11:20 HULA- How Harbor-UCLA Jumps Through Hoops to Save Legs – Dr. Fred Bongard and Dr. Ashley Miller
11:20 – 11:30 How an Outpatient Angio Suite Two Steps to Success in Saving Limbs in the Heart of Texas – Dr. Robert Feldtman
11:30 – 11:40 A Decade Behind the Delhi Counter: Reducing Amputations in India – Dr. Rumneek Sodhi
11:40 – 11:50 How Can We Collectively Raise Our C Average? Improving Care for a Common, Costly and Complex Condition – Dr. Neal Barshes
11:50 – 12:30 Panel Discussion
12:30 – 1:40 Overlapping Lunch Symposium (non CME/CPME)
Sponsor: Abbott Vascular – Third Houston Toe and Flow Symposium – Legends I
Sponsor: Acelity – Disposable NPWT for the Outpatient Setting – Dr. Christopher Barrett & An Introduction to Advanced Wound Dressings – Melania Howell Taylor – Legends II
DEVICES
Portrait of the Doctor as a Young Geek – Time to Re-Joyce or Re-Assess?
Moderator: Dr. David Armstrong
1:40 – 2:00 Wearables are Passe: How About Injectables? Dr. Miguel Montero-Baker
2:00 – 2:20 Diabetic Foot Surgery for the Patient in Remission – Dr. John Steinberg
2:20 – 2:40 Socksess at CES: How the Diabetic Foot and Smart Sox Took Over the Consumer Electronics Show – Ran Ma
2:40 – 3:00 A New Sockratic Method for Answering Age-Old Rhetorical Questions: Are Smart Socks and Intelligent Textiles Here To Stay? – Davide Vigano
3:00 – 3:20 I, Claudicant: How Wearables are Measuring and Managing our Way to a Better Republic – Dr. Iraklis Pipinos
3:20 – 3:40 The Robot – the Widget in our Wardrobe: How Wearable Robots are Transforming More than Meets the Eye- Dr. Joe Hitt
3:40 – 4:00 Panel Discussion
4:00 – 4:20 Break
Charcot Foot
Moderator: William Jeffcoate
4:20 – 4:40 Defining Charcot – Dr. Uli Illgner
4:40 – 5:00 Denosumab (RANKL for Charcot) – Dr. Matthew Malone
5:00 – 5:20 Surgical Therapy – Dr. Keith Goss
5:20 – 5:40 A Worldwide Registry – Dr. Fran Game
5:40 – 6:00 Panel Discussion
6:00 – 7:30 Welcome to #DFCon17 Reception – Open Exhibits (non CME/CPME)
Friday – March 24, 2017
6:45 – 7:00 Registration
7:00 – 8:00 Overlapping Breakfast Symposia (non CME/CPME)
Sponsor: Osiris Therapeutics – Clinical and Scientific Advances in the Use of Cryopreserved Placental Membranes – Dr. Dan Davis – Legends I
Sponsor: Woundcare-Circle – The ABC’s of Off-loading – Alpha to Omega – Healing to Remission – Dr. Lawrence Lavery – Legends II
Sponsor: Tissue Regenix – Can You Heal Me Now? DermaPure Signals an Exciting Change and Better Coverage for Dermal Regeneration – Dr. Randy Lepow – Legends III
(Videos)
Moderator: Dr. Joseph L. Mills, Sr.
8:00 – 8:10 Pedal Bypass – Dr. Neal Barshes
8:10 – 8:20 Retrograde Access – Dr. Miguel Montero-Baker
8:20 – 8:30 The Outer Limits of Endovascular Therapy – Dr. John Rundback
8:30 – 8:40 The Many Ways to Skin a Foot: Damage Control Debridement – Dr. Chris Attinger
8:40 – 8:50 Indocyanine Green-Directed Foot Salvage – Dr. Joseph L. Mills, Sr. and Dr. Jeffrey Ross
8:50 – 9:10 Novel Ways to Assess Frailty – Dr. Bijan Najafi
9:10 – 9:30 Break
Limb salvage maintenance: Managing the Diabetic Foot In Remission
Common Sense to Avoid ToeMas Paine: The Diabetic Foot in Remission and other Quiet Revolutions
Moderator: Dr. Chris Attinger and Dr. Giacomo Clerici
9:30 – 9:50 Fat Chance: Can Fat Grafting Give Patients More Cushion For Push-Off? – Dr. David G. Armstrong
9:50 – 10:10 Defining Diabetic Foot Remission: Ulcer-Free Days – Dr. Gerry Rayman
10:10 – 10:30 Measuring Vascular Remission: Is It More Than Just Restenosis? – Dr. Michael Conte
10:30 – 10:50 Sensors and Sensibility: Romantic or Plain Jane? Pride or Prejudice? –Dr. Bijan Najafi
10:50 – 11:15 Panel Discussion
11:15 – 11:40 The 13th Annual Edward James Olmos Award – For Advocacy in Amputation Prevention
11:40 – 2:00 Lunch / Exhibits – Poster Presentations and Awards
12:30 – 1:30 Lunch Symposium (non CME/CPME)
Sponsor: EO2 Concepts – Oxygen in Wounds – Real or Hot Air? – Mark Niederauer, PhD, Klearchos Papas, PhD, and Dr. Mark Couture
Peripheral Artery Disease
Moderator: Dr. George Andros and Dr. Gary Gibbons
2:00 – 2:20 Smart Biomaterials and Polymeric Paving: Pathway to Endoluminal Paradise? – Dr. Marv Slepian
2:20 – 2:40 Drug-eluting Technology: Form of the Future or Merely a Passing Fancy? – Dr. Miguel Montero-Baker
2:40 – 3:00 Lord of the Rings of Risk: Precious Pearls for Promotion of Pulsatility – Dr. Joseph L. Mills, Sr.
3:00 – 3:20 Complex Endovascular Techniques – Dr. John Rundback
3:20 – 3:40 Who Still Needs a Bypass? – Dr. Michael Conte
3:40 – 4:00 Panel Discussion
4:00 – 4:20 Studio Break
A Topical Discussion on Topical Therapy for Infections – Incisions, Debridements, Successes and Failures
Moderator: Dr. David G. Armstrong and Dr. Gary Gibbons
4:00 – 4:20 The Wound Microbiome and New Approaches to Topical Therapy – Dr. Bonnie Hurwitz
4:20 – 4:40 Why and How to Overcome Biofilm in Diabetic Foot Infections – Dr. Matthew Malone
4:40 – 5:00 Topical Antimicrobial Therapy for Diabetic Foot Wounds: A Cochrane Systemic Review – Dr. Benjamin A. Lipsky
5:00 – 5:20 The One Step Trials of Topical Pexiganan Cream vs. “Placebo” for Mild Diabetic Foot Infections – Dr. Warren Joseph
5:20 – 6:00 Panel Discussion
Saturday – March 25, 2017
6:30 – 7:00 Registration
6:30 – 7:00 Breakfast
Unopposed Company Supported Workshops
Topics may include but are not limited to: offloading and wearable technology, NPWT, bioengineered tissue, diagnostics, and other vascular/diabetic foot techniques. (non CME/CPME)
8:00 – 12:00 Noninvasive Testing
Sponsors: SPY and VASAMED
– Dr. Joseph L. Mills, Sr. and Dr. Jeffrey Ross
– Legends I
Offloading Workshop
Sponsor: BSN medical
– Dr. Bijan Najafi, Dr. Jeffrey Ross and Dr. Eric Espensen
– Legends II
Pedal Access Workshop
Sponsor: Cook Medical
– Dr. Miguel Montero-Baker
– Legends III
Skin Substitutes
Sponsor: Integra LifeSciences
– Dr. Jeffrey Ross and Dr. Eric Espensen
– Legends V
11:00 – 1:00 Lunch / Exhibits
11:30 – 12:30 Lunch Symposium (non CME/CPME)
Sponsor: W.L. Gore – Legends VI
Vascular
Moderator: Dr. Joseph L. Mills, Sr. and Dr. George Andros
1:00 – 1:20 Streamlining Vascular Care – Dr. Darren Schneider
1:20 – 1:40 To Stent or Not to Stent? What Lesions Require Stenting and What Stent Should Be Chosen? – Dr. Jayer Chung
1:40 – 2:00 Atherectomy: Debulking and Debunking the Data! – Dr. Miguel Montero-Baker
2:00 – 2:20 Panel Discussion
Conclusions
Moderator: Dr. Joseph L. Mills, Sr. and Dr. David G. Armstrong
2:00 – 2:20 Implementing a National Diabetic Foot Program – Dr. Roberto Anichini
2:20 – 2:40 Integrating Diabetic Foot Care to Improve Outcomes and Cost Effectiveness – Dr. Gary Gibbons
2:40 – 3:00 A Worldwide Registry: Where Can I Sign Up? – Dr. Kristien Van Acker
3:00 – 3:20 Panel Discussion
3:20 – 3:55 Summary – Dr. Andrew Boulton
3:55 – 4:00 Closing Remarks – Dr. Joseph L. Mills, Sr. and Dr. David G. Armstrong
.10-12+ post conference price target! I've been saying this for a month, it will come.
READ ALL THESE POSTS BELOW!!
We are a screaming BUY here people! Spread the word!!
DrDave951 Friday, 03/03/17 03:11:33 PM
Re: txhighopes post# 13256
Post # of 15110
Poster sessions mean exactly that... you put your poster up in a room (with many other poster presenters all in the same room), and conference attendees walk around and look at all the posters. Generally (but not always), the posters are available for you to walk around and look at at your leisure for a few hours, and then there is time reserved for "poster presenters" (those who did the research and prepared the poster) to be at their poster in order to talk to conference attendees. The time mentioned in this post (11:40-2:20) is when the poster will be available for conference attendees to look over the posters, but generally the "presenters" aren't standing at their posters for the entire three hours. This conference might be different, but usually the last hour or so is when the "presenters" are expected to be there to talk to people. Poster presentations like this, which allows a lot of one-on-one interaction with interested parties, are very productive, as you can answer questions and engage in dialogue with anyone who is interested in your research (as opposed to a standard seminar or "paper" presentation, where you stand in front of a large crowd and explain your results with little or no interaction with the audience). Word usually spreads pretty quickly about posters (research findings) which are exceptional, so hopefully Dr. Otiko will be chatting with a large number of conference attendees!
>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>
February 8, 2017
~ CEO speaking at the Global Diabetic Foot Conference in Houston March 24, 2017 ~
http://www.marketwired.com/press-release/dr-chris-ayo-otiko-president-viaderma-inc-is-selected-write-article-healing-diabetic-otc-pink-vdrm-2194656.htm
https://www.drugs.com/otc/676986/viabecline.html
https://www.linkedin.com/pulse/healing-diabetic-ulcers-dave-pozek-1
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=129403043
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=129390203
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=129368069
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=129334996
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=129312100
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=129311752
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=129297007
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=129296364
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=129295215
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=129286262
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=129196331
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=129040891
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=128962099
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=128961948
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=128957163
ABSTRACT in brief
Author: Christopher Otiko DPM
BACKGROUND
Diabetes affects almost a half a billion people globally with 23 million affected in the US. With about 83 million affected with condition designated as pre-diabetes. Of those with diabetes, 50% will develop peripheral neuropathy and/or diabetic ulcers. Of the 23 million people affected with diabetes, 25% will develop diabetic ulcers many will require expensive therapy or invasive surgical amputations.
OBJECTIVE
The goal of this study was to evaluate the efficacy and safety of FDA registered OTC Viabecline tetracycline hydrochloride. A topically applied antibiotic ointment designed for the treatment of diabetic foot ulceration.
RESEARCH DESIGN AND METHODS
Clinical investigation (CI) documenting the treatment effectiveness was estimated by enrolling consecutive patients in a multi-center outpatient clinic setting.
RESULTS
Viabecline was more effective than standard care, including IV antibiotics. The effect was greatest in those with the most severe wounds, i.e., large wounds that affect deeper anatomical structures. These patients were last resort patients that had failed all previous care and were headed to an amputation. In some cases even an amputation wasn’t feasible because of the patient’s cardiac status.
CONCLUSIONS
Viabecline is more than 96% effective in healing diabetic foot ulcers within 4 weeks. This effect is more pronounced in more severe wound, and the effect is the same whether the wound is infected or not.
BACKGROUND
Diabetes affects almost a half a billion people globally with 23 million affected in the US [2]. With about 83 million affected with condition designated as “pre-diabetes.”[3] Of those with diabetes, 50% will develop peripheral neuropathy and/or diabetic ulcers. [4] Of the 23 million people affected with diabetes, 25% will develop diabetic ulcers many will require expensive therapy or invasive surgical amputations [5].These wounds are often multifactorial in origin, but tend to occur on the plantar surface of the foot and arise in the setting of peripheral neuropathy, vascular compromise or both. Diabetic foot ulcers are associated with increased morbidity and mortality, and they have a negative impact on both the quality of life and the productivity of diabetic patients [6]. Almost 80,000 people (US) will require lower extremity amputations (LEAs) every year. Of those who require amputations, and depending on which study you choose, one year mortality rates of 10 to 50 percent, and the 5-year mortality rate post-LEA is between 30 and 80 percent.[7-12] Costing about $245 billion in 2012 and cost $365 billion in 2016 [13-15]
OBJECTIVE
The goal of this study was to evaluate the efficacy and safety of FDA registered Viabecline, tetracycline hydrochloride, a new topical antibiotic ointment. [16] Viabecline is a topically applied antibiotic designed for the treatment of diabetic foot ulceration as well as for other basic wound care needs.
RESEARCH DESIGN AND METHODOLOGY
Given the degree of severity of the patient’s condition(s) they were treated consecutively utilizing the multicenter approach. The majority of the patients were treated at Dr. Christopher Otiko practice and at various hospitals and rehab centers in Southern California.
Briefly, subjects were chosen for this study if they were patients with confirmed diabetes who had an ulcer on their foot. Additionally, 90% of these patients were “last resort” patients. Those selected to participate were patients who had failed all previous care and were headed for an amputation or had a non-healing wound for more than 6 months. In some cases even an amputation was problematic because of the patient’s cardiac status.
The wounds were classified using The Wagner-Meggitt classification is based mainly on wound depth and consists of 6 wound grades.[17] These include: grade 0 (intact skin), grade 1
(superficial ulcer), grade 2 (deep ulcer to tendon, bone, or joint), grade 3 (deep ulcer with abscess or osteomyelitis), grade 4 (forefoot gangrene), and grade 5 (whole foot gangrene) APPLICATION
Viabecline Protocol: One or two drops externally applied topical solution directly to the ulcer and rubbed into skin for 30 seconds three times daily. Ulcer was covered with non-sterile gauze dressing.
Patient data
Sex Male: 12. Female: 16
Average Age (years) 69.5
Wound area (cm2) average 1.89
Wound duration (weeks) 16
Wound grade 2.01?(1.98–2.04)
Diabetes type T1/8 – T2/20
Insulin dependent 6
Non-insulin dependent 22
Infected 8
CLINICAL OUTCOMES Study end point
We used an end point of 20 weeks for assessing whether a patient healed. However, 27 out of 28 patients healed within 4 weeks.
One patient who had an exposed necrotic extensor tendon took the longest; 12 weeks. He also had end stage renal disease and peripheral vascular disease which attributed to the delayed healing. Because we wanted to ensure adequate follow up we extended the treatment time to at least 12 weeks, our actual end point was a healed wound within the subsequent 4 weeks. We did this to be consistent with other studies on the efficacy of diabetic foot ulceration therapy. Many of these studies treated patients who had already failed to heal with standard therapy with an investigational agent for 20 weeks
CLINICAL OUTCOMES Study end point (continued)
Of the 28 patients in this study, 100% were treated with Viabeclne and healed by the 12th week of care Patients treated were more likely to have larger wounds, older wounds, and wounds of higher grade. Overall, 27 out of 28 patients (96% of patients) healed within 4 weeks of the initiation of care. The patient had an exposed necrotic extensor tendon took the longest to heal (12 weeks). The patient also had end stage renal disease and peripheral vascular disease which attributed to the delayed healing. His treatment continued at home where his daughter who was a Certified Nurse’s assistant (CNA) applied Viabecline 3 times daily until his ulcer healed in a total time of 12 weeks.
CONCLUSION
This study is the first independent assessment of the efficacy of Viabecline in the treatment of diabetic foot ulcers. We found that Viabecline is very effective in the treatment of diabetic foot ulceration. It appears that Viabecline can be used in minor wounds, but possibly, is more likely to be used in more severe wounds and may be more effective than standard care for severe wounds.
Most patients treated with Viabecline did not begin this treatment until the 3rd month with the ulcer and the Viabecline was the last resort. One patient had a confirmed diagnosis of MRSA that had not responded to 6 weeks IV Vancomycin treatment. Previous studies that examined the efficacy of treatments for diabetic foot ulceration have often used the cutoff of twenty (20) weeks of care. Our study revealed that we achieved healing after only 4 weeks of treatment. We used 20 weeks of care as our study end point. Viabecline treatment typically ended after only 4 weeks on average. Patients in our study had a four (4) week treatment period and a total 20-week observation follow up period. This is consistent with our in house pre-CI that suggests that most infections are under control in about a week and near complete wound recovery in four (4) to six (6) weeks. Previous established therapeutic strategies [18] could take up to twenty weeks (20) then the percentage of healed diabetic neuropathic foot ulceration levels off after approximately five (5) months. This indicates very little increased healing after the 20 week mark. Whereas 96% of our patients all healed within 4 weeks using Viabecline one (1) to three (3) times daily depending on the condition of the patient.
We found that Viabecline healed 96% diabetic neuropathic foot ulcers after 4 weeks of care when compared with treatment using standard care alone. The relative benefits of Viabecline over standard care persist for wounds of all sizes (with or without and infections) and the relative risk of healing using Viabecline versus standard care increases with wounds that are larger and more severe. In the setting of this study, these were also the patients more likely to be treated with Viabecline. Therefore, Viabecline represents an effective treatment for diabetic foot ulceration. Viabecline also appears to be effective in severe wounds, and may therefore play an important role in preventing amputation
CONCLUSION: Forward looking statement
Based on the positive results of the previous CI’s this investigator recommends further study into the efficacy of Viabecline topical antibiotic ointment. Initiating a phase two clinical investigation, including recruiting a larger cohort and using the multi-center approach and adding the double blind and placebo controls to further document the efficacy of the product and protocols. Successful implication of these protocols will positively affect clinical outcomes and be beneficial when used in expanding these procedures globally. Together this may lead to wide spread use and may reduce the staggering numbers of amputation’s and corresponding deaths, and may reduce the nearly 1.4 trillion dollars spent (US) yearly treating diabetes.
Conflict of Interest statement: Author states there is no conflict of interest issues related to this study
Acknowledgements David R Pozek
REFERENCES:
1) Author: Christopher Otiko DPM
6650 Reseda Blvd, Suite 101A, Reseda, Los Angeles County, CA 91335
2) In 2013, according to International Diabetes Federation, an est 381 million people had diabetes https://en.wikipedia.org/wiki/Epidemiology_of_diabetes_mellitus
3) In 2012, 29.1 million Americans, or 9.3% of the population, had diabetes.
http://www.diabetes.org/diabetes-basics/statistics/#sthash.7S3t2HMw.dpuf
4) Diabetic neuropathy is the most common complication of diabetes mellitus (DM), affecting as many as 50% of patients with type 1 and type 2 DM http://emedicine.medscape.com/article/1170337-overview
5) The Cost of Diabetes ADA http://www.diabetes.org/advocacy/news-events/cost-of-diabetes.html
6) 25% of the people with diabetes will develop foot ulcers http://www.medscape.com/viewarticle/821908
7) Diabetes is the leading cause of non-traumatic lower extremity amputations in the United States http://www.apma.org/Learn/FootHealth.cfm?ItemNumber=981
8) Tentolouris N, Al-Sabbagh S, Walker MG, et al. Mortality in diabetic and nondiabetic patients after amputations performed from 1990 to 1995: a 5-year follow-up study. Diabetes Care.
2004;27(7):1598–1604.
http://www.ncbi.nlm.nih.gov/books/NBK65149/
REFERENCES:
9) Larsson J, Agardh CD, Apelqvist J, et al. Long-term prognosis after healed amputation in patients Clin Orthop Relat Res. 1998;350:149–158.
[PubMed] http://www.ncbi.nlm.nih.gov/books/NBK65149/
10) Reiber GE, LeMaster JW. Epidemiology and economic impact of foot ulcers and amputations in people with diabetes. In:Bowker JH, Pfeifer M, editors. Levin and O’Neal’s the diabetic foot.
Philadelphia: Mosby- Elsevier; 2008. pp. 3–22. http://www.ncbi.nlm.nih.gov/books/NBK65149/
11) Diabetic foot infections are a frequent clinical problem. About 50% of patients with diabetic foot infections
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4218993/ have foot amputations die within five years.
12) According to the American Diabetes Association, the annual cost of diabetes, which affects 22.3 million people in the U.S., was $245 billion in 2012: $176 billion in excess health care expenditures and $69 billion in reduced workforce http://care.diabetesjournals.org/content/37/3/651 (2012)
13) Diabetes and prediabetes cost America $322 billion per year - : http://www.diabetes.org/diabetes- basics/statistics/infographics/adv-staggering-cost-of-diabetes.html#sthash.vas8Kkg4.dpuf (2016) http://www.diabetes.org/diabetes-basics/statistics/infographics/adv-staggering-cost-of- diabetes.html
14) Costs of treating diabetic wounds NZD(Of every 3.5 wound episodes, one required a major amputation)* Joret MO1, Dean A2, Cao C3, Stewart J4, Bhamidipaty V5. http://www.ncbi.nlm.nih.gov/pubmed/27565588
15) COSTS of Treating Diabete’s in the US AMERICAN DIABETIES Association
The American Diabetes Association (Association) released new research on March 6, 2013 estimating the total costs of diagnosed diabetes have risen to $245 billion in 2012 from $174 billion in 2007
http://www.diabetes.org/advocacy/news-events/cost-ofdiabetes.html?gclid=Cj0KEQjwxqS- BRDRgPLp0q2t0IUB
16) VIABECLINE- tetracycline hydrochloride (Topical ointment) V-LABS LLC
17) The Choice of Diabetic Foot Ulcer Classification in Relation to the Final Outcome http://www.medscape.com/viewarticle/430891_4
18) Wieman TJ, Smiell JM, Su Y: Efficacy and safety of a topical gel formulation of recombinant human http://www.ncbi.nlm.nih.gov/pubmed/9589248
LOL...omg too funny